CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ginkgo Bioworks Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ginkgo Bioworks Holdings Inc
27 Drydock Avenue, 8Th Floor
Phone: (310) 209-7280p:310 209-7280 BOSTON, MA  02210  United States Ticker: DNADNA
Business Summary
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Founder, Chief Operating Officer, Director ReshmaShetty 42 1/1/2021 1/1/2021
Chief Executive Officer, Founder, Director JasonKelly 42 1/1/2021 1/1/2021
Chief Financial Officer MarkDmytruk 51 1/1/2021 1/1/2021
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Altar 5 rue Henri Desbrueres Evry France
Circularis AB V?nnerberga G?rd ! C/O Jan Nystedt S?DERK?PING SE
Zymergen Inc 1440 Stanford Avenue EMERYVILLE CA United States
7 additional Subsidiary records available in full report.

Business Names
Business Name
ALTAR
Circularis
Circularis AB
15 additional Business Names available in full report.

General Information
Number of Employees: 1,218 (As of 12/31/2023)
Outstanding Shares: 2,152,395,786 (As of 2/22/2024)
Shareholders: 721
Stock Exchange: NYSE
Federal Tax Id: 872652913
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024